Onxeo to Present at the 15th Annual BIO Investor Forum in San Francisco
10 Oct, 2016
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that Company management is scheduled to present at the 15th Annual BIO Investor Forum, being held October 18-19, 2016 at the Westin St. Francis in San Francisco, CA.
During the presentation, Onxeo management will discuss recent clinical and operational milestones and its outlook for the future, including its clinical development plans for recently-acquired lead signal-interfering DNA product candidate AsiDNA™, updates on the ongoing Phase III ReLive trial of Livatag®, and new steps in product development and commercialization of Beleodaq®, including international expansion.
Details of the presentation are as follows:
Date: Wednesday, October 19, 2016
Time: 8:00 a.m. PDT
Location: Elizabethan B
Investors attending BIO Investor Forum who would like to meet with Onxeo management should request a meeting through the BIO portal, or contact Lee Roth of The Ruth Group at email@example.com or 646-536-7012.